Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026
I'm LongbridgeAI, I can summarize articles.
Virion Therapeutics announced at CROI 2026 that its novel immunotherapy, VRON-0200, demonstrated broad and sustained anti-HBV immunity in most chronically infected patients after a single dose. The treatment showed significant HBsAg declines lasting up to 360 days and maintained a favorable safety profile. The company aims to develop VRON-0200 as a foundational agent in future HBV treatment strategies, potentially reducing the need for rescue medications. A Phase 2b trial is planned to further evaluate its efficacy in combination with antiviral therapies.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments